Context: Patients with nonalcoholic fatty liver disease have a high cardiovascular risk, but statins are rarely prescribed because of fear of hepatotoxicity.
. It is characterized by insulin resistance and the coexistence of other components of the metabolic syndrome (MetS), such as obesity, prediabetes or type 2 diabetes (T2DM), hypertriglyceridemia with increased apolipoprotein B secretion, low high-density lipoprotein cholesterol (HDL-C), and small, dense low-density lipoproteins (LDLs) (3, 4) .
Patients with NAFLD are at increased risk of cardiovascular disease (5) . Many mechanisms have been postulated to explain this association (i.e., more severe insulin resistance, subclinical inflammation, ectopic fat accumulation with potential cardiolipotoxicity, and worse dyslipidemia) (6, 7) . Because of their highly atherogenic profile, patients with NAFLD are excellent candidates for the use of statins (8) .
Unfortunately, concerns remain regarding their safety in patients with NASH, especially in those with elevated plasma aminotransferases. There is a belief among clinicians that patients with NASH are at a higher risk for hepatotoxicity when prescribed a statin (9) , and it has even been postulated that statins could increase hepatic fat accumulation in patients with NAFLD (10) . This perception has had serious clinical implications because many patients with NAFLD are denied statins and other lipid-lowering therapies on a daily basis (11) . For instance, a previous report found that only 9% of 638 patients with NAFLD were treated with a statin, despite most of them having dyslipidemia (12) . The use of statins was also significantly low (45%) in a cohort of 346 patients with T2DM and NAFLD (13) .
Some studies have suggested that statins may be safe in patients with NAFLD, but these studies have had serious limitations imposed by their cross-sectional (12, 14) or retrospective (15) (16) (17) nature. More important, most lacked a histologic diagnosis of NASH (12, 15, 16, (18) (19) (20) (21) (22) , as recently reviewed elsewhere (23) . The few prospective studies in patients with NASH have been short (#12 months) and included only 5 to 43 patients (24) (25) (26) (27) (28) . Overall, results for plasma aminotransferases, hepatic steatosis, and histology were rather inconsistent, with some of these studies even showing mild beneficial effects of statins in NASH (29) .
The aim of the current study was to perform a longterm prospective evaluation of the safety of statins in patients with prediabetes or T2DM and biopsyproven NASH.
Methods

Patients
A total of 101 patients were recruited from the general population of San Antonio, Texas, between December 2008 and 2014, as part of a randomized controlled trial (RCT) assessing the long-term efficacy of pioglitazone in patients with NASH.
Complete inclusion/exclusion criteria and results from the main study have been previously reported (30) . In summary, the study included patients aged 18 to 70 years with prediabetes or T2DM and biopsy-proven NASH. They were identified from responses to local newspaper advertisements and were diagnosed with NAFLD during a screening with proton magnetic resonance spectroscopy ( 1 H-MRS) or from referrals from endocrinology and hepatology clinics. Participants were in good general health without evidence of any significant chronic disease, as determined by history, physical examination, routine blood and urine chemistries, and electrocardiography. Patients with established cardiovascular disease were not excluded from the trial as long as they were stable for at least 6 months before screening. Volunteers were excluded if they had a history of alcohol abuse ($30 g/d in men or $20 g/d in women); liver disease other than NASH (i.e., hepatitis B or C, autoimmune hepatitis, hemochromatosis, Wilson disease, drug-induced hepatitis); type 1 diabetes; or a history of clinically significant renal disease, pulmonary disease, or congestive heart failure (New York Heart Association classification .II). The study was approved by the University of Texas Health Science Center at San Antonio institutional review board, and each patient provided written informed consent before participation.
Study design
After enrollment, there was a run-in phase of ;4 weeks, in which baseline metabolic studies were performed (see below). During this phase, patients not taking a statin were prescribed therapy if indicated (31, 32) . In patients already taking a statin, the dosage was titrated as needed to achieve LDL-cholesterol (LDL-C) targets, in accordance with prevailing guidelines at the time (31) .
Baseline metabolic measurements included (1) fasting plasma glucose, hemoglobin A1c, lipid profile, plasma aminotransferase levels, insulin, and free fatty acids; (2) total body fat by dual-energy x-ray absorptiometry; (3) liver fat content by 1 H-MRS; (4) euglycemic hyperinsulinemic clamp with 3-[ 3 H] glucose for the measurement of glucose turnover; (5) 75-g oral glucose tolerance test to diagnose normal glucose tolerance or T2DM according to current criteria (32); and (6) liver biopsy to diagnose NASH and determine the grade and stage of the disease.
After the preceding baseline metabolic measurements were performed, patients were prescribed a hypocaloric diet (500-kcal/d deficit from the calculated weight-maintaining diet) and followed every 1 to 2 months at the clinical research center by research staff. During follow-up visits, vital signs, physical examination, home glucose monitoring results (if individuals had diabetes), adverse events, medication adherence, and blood chemistries were assessed. On the basis of guidelines criteria, patients who were not started on statins during the run-in phase were prescribed a statin when required (or, on occasion, the dose titrated) during follow-up as needed to reach lipid treatment goals. In patients who completed 18 and 36 months of follow-up, we repeated the metabolic studies and liver biopsy as part of the trial evaluating the use of pioglitazone vs placebo in patients with NASH (30) . Liver 1 H-MRS and euglycemic hyperinsulinemic clamp were performed only at baseline and month 18. To assess the safety of statins regarding liver function, we measured plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at enrollment, at baseline, and at every follow-up visit.
Measurements of total body and liver fat content
Total body fat content was measured by dual-energy x-ray absorptiometry (Hologic Inc., Waltham, MA). For the measurement of hepatic fat content, localized 1 H-MRS of the liver was performed on a Siemens TIM-Trio 3.0-T magnetic resonance imaging whole-body scanner (Siemens Healthcare, Erlanger, Germany), using methods previously described (33) . A liver fat content .5.5% was considered diagnostic of NAFLD (34) .
Euglycemic hyperinsulinemic clamp
After an overnight fast, patients underwent a two-step euglycemic hyperinsulinemic clamp with the infusion of 3-[ 3 H] glucose as previously described (35) . A primed [25 mCi 3 (fasting glucose/100)] continuous (0.25 mCi/min) infusion of 3-[ 3 H] glucose (DuPont-NEN, Boston, MA) was initiated and continued until the end of the study. After the basal equilibration period, insulin was administered as a primed continuous infusion at 10 mIU/(m 2 3 minute) for 120 minutes to assess suppression of endogenous glucose production, followed by another 2 hours at an infusion rate of 80 mIU/(m 2 3 minute) to assess skeletal muscle insulin-stimulated glucose disposal. A variable infusion of 20% glucose was adjusted according to the negative feedback principle to maintain the plasma glucose concentration at approximately 90 to 100 mg/dL with a coefficient of variation ,5%.
Liver biopsy
An ultrasonography-guided liver biopsy was performed in patients with elevated liver aminotransferase levels when all other causes of liver disease were ruled out, or in patients with normal liver aminotransferase levels if they were diagnosed with NAFLD by 1 H-MRS and had significant risk factors for the development of NASH, such as T2DM, MetS, and/or insulin resistance. Biopsy specimens were evaluated by a pathologist who was unaware of the patients' identity or clinical information. Histologic characteristics for the diagnosis of NASH were determined using standard criteria (36) .
Statistical analysis
Data were summarized in percentages for categorical variables and as mean 6 standard error of the mean for numeric variables, except for plasma triglyceride concentrations, which were expressed as median (interquartile range). Comparisons between two groups were performed with x 2 or Fisher exact test for categorical variables and Kruskal-Wallis or Student t test for numeric variables depending on their distribution. Changes in continuous variables within groups (before vs after) were tested by means of Wilcoxon signed-rank test or paired t test depending on the variables' distribution. A two-tailed P value ,0.05 was considered to indicate statistical significance. Analyses were performed with Stata software, version 11.1 (Stata Corp. LP, College Station, TX).
Results
Patient characteristics at enrollment
We enrolled and followed 101 patients with biopsyproven NASH. Table 1 summarizes patient characteristics according to whether they were receiving or not receiving a statin at enrollment. Body mass index (BMI), total body fat, and presence of the MetS did not significantly differ between statin users and nonusers. As expected, patients receiving statins were slightly older (55 6 1 years vs 48 6 1 years; P , 0.001) and had a trend toward higher prevalence of T2DM (63% vs 44%; P = 0.07). We also observed a strong trend toward a lower percentage of women among patients already receiving statin therapy at enrollment (18% vs 37%; P = 0.05). Although patients receiving statins had lower plasma levels of total cholesterol (166 6 6 vs 196 6 6 mg/dL; P , 0.001) and LDL-C (93 6 5 mg/dL vs 119 6 5 mg/dL; P , 0.001), we found no differences regarding plasma triglyceride or HDL-C concentration between the groups.
Patients receiving a statin had lower levels of plasma ALT (57 6 5 IU/L vs 75 6 5 IU/L; P = 0.03), and this was associated with lower liver fat content by 1 H-MRS (146 1% vs 1961%; P = 0.02). However, histologic severity of NASH did not significantly differ between statin users and nonusers in steatosis, inflammation, ballooning, or fibrosis (Table 1) .
Only 37% of patients with NASH at enrollment were receiving statins and 12% were receiving other lipidlowering drugs [fenofibrate (n = 2), gemfibrozil (n = 7), niacin (n = 2), and fish oil (n = 1)] despite the overall high cardiovascular risk of this population. Most patients not prescribed a statin had a clear indication based on the guidelines at the time (31, 32) , given the high prevalence of obesity (81%), T2DM (51%), MetS (89%), and dyslipidemia (59% with plasma triglyceride levels . 150 mg/dL, 55% with LDL-C levels . 100 mg/dL, and 74% with low HDL-C levels). The statin most frequently used at enrollment was simvastatin (84% of statin users), followed by rosuvastatin (11%), influenced largely by the local health care plan formulary guidelines at the time of the study. Statins doses were classified as low (#10 mg of simvastatin, 20 mg of lovastatin, or 10 to 20 mg of pravastatin), medium (20 to 40 mg of simvastatin, 40 to 80 mg of pravastatin, 10 to 20 mg of atorvastatin, or 5 to 10 mg of rosuvastatin), and high (40 to 80 mg of atorvastatin or 20 to 40 mg of rosuvastatin) according to recent guidelines (37) . Only 8% of the patients were receiving high-intensity statin therapy at enrollment, whereas the majority (79%) of patients were receiving moderateintensity therapy. Overall, patients receiving statins at enrollment were undertreated, with high percentages of patients out of lipid targets according to current guidelines (51% with triglyceride levels . 150 mg/dL, 35% with LDL-C levels .100 mg/dL, and 65% with low HDL-C levels).
Short-term safety of statin therapy (before and after run-in phase)
At the beginning of the run-in phase (average of ;4 weeks), patients had upward titration of statin dose or were started on a statin according to prevailing guidelines at the time (31, 32) . Patients not prescribed a statin at this time had a contraindication for these drugs or were unwilling to start them.
Among patients who were newly prescribed a statin during the run-in phase, most were started cautiously on a low or medium dose (45% and 48%, respectively). As expected, statin initiation led to a significant reduction in plasma total cholesterol (P , 0.002) and LDL-C (P = 0.003). No deleterious effects on plasma aminotransferase concentration or the proportion of patients with elevated plasma aminotransferases were observed after statin initiation. None of the patients newly started on a statin experienced any significant increase in plasma ALT or AST levels (defined as a twofold elevation) during the run-in phase. Indeed, patients newly prescribed a statin and those already taking a statin before enrollment showed a slight reduction of plasma ALT during this phase (from 64 6 4 IU/L to 56 6 3 IU/L; P = 0.007). This was associated with a small reduction in BMI (from 34.4 6 0.5 kg/m 2 to 34.1 6 0.5 kg/m 2 ; P = 0.007).
During this phase, 13 patients with plasma ALT or AST levels .80 IU/L were prescribed a statin despite their significant elevation of plasma aminotransferase concentration. Plasma aminotransferase levels did not increase further among this group of patients. In fact, mean plasma ALT and AST significantly decreased during the run-in phase after statin initiation in this group of patients [from 109 6 6 IU/L to 83 6 5 IU/L (P = 0.001) for plasma ALT and from 66 6 5 IU/L to 53 6 5 IU/L (P = 0.01) for plasma AST]. Among patients who were already receiving a statin at enrollment, 28% had an upward titration of their dose during the run-in period, resulting in an increase in the number of patients in the medium-and high-dose group (from 28% to 33% and from 28% to 36%, respectively). Upward titration of statin dose during this phase led to a further decrease in plasma total cholesterol (189 6 12 mg/dL vs 145 6 9 mg/dL; P = 0.01) and LDL-C (114 6 15 mg/dL vs 68 6 7 mg/dL; P = 0.004) levels and a trend toward lower median plasma triglyceride [190 (126 to 299) mg/dL vs 126 (111 to 154) mg/dL, P = 0.06] concentrations. Overall, mean plasma ALT and AST levels did not change in this group during this period or later. Regarding the hepatic safety of statin titration, only one patient in whom the statin was increased from low to medium dose had a twofold increase in plasma ALT concentration that spontaneously returned to baseline at the next follow-up visit without any active measure. Two patients not receiving statins during the run-in phase also showed an elevation in plasma aminotransferase levels that returned to normal spontaneously. 
Follow-up
A total of 86 patients receiving statins and 15 not receiving statins with biopsy-proven NASH were followed as part of a pioglitazone vs placebo randomized clinical trial (30) for a total of 194 patient-years of statin therapy (range, 0.1 to 3 years). Eighteen of the 101 patients were prematurely discontinued from the study after a mean follow-up of 7 months (range, 1 to 16 months) because of loss to follow-up or other causes unrelated to statin use. Most withdrawals were due to safety concerns with pioglitazone and bladder cancer at the time of a report suggesting such an association, as detailed elsewhere (30) . We found no significant differences in clinical and laboratory measures between patients discontinued and the rest of the participants. Of these patients, 12 were receiving statins at the time of disenrollment and the remaining 6 were never prescribed a statin. Only 1 patient discontinued statins during followup against medical advice. No drug-related adverse events were identified in this patient.
After all patients were started on statins, 67% of them were taking simvastatin, 21% were taking rosuvastatin, and the remaining 12% were equally divided between atorvastatin and pravastatin. At the end of the study, only 30% of patients were receiving a low-dose statin, whereas the rest were receiving medium-or high-dose therapy (46% and 24%, respectively). Approximately 21% of patients receiving a statin were taking combination therapy at the end of the study [fenofibrate (n = 4), gemfibrozil (n = 11), niacin (n = 2), and fish oil (n = 1)].
Long-term safety
As can be observed in Fig 1(a) , plasma ALT levels tended to decrease over time in all patients receiving pioglitazone, whether they were taking statin therapy or not, likely because of the effects of the thiazolidinedione on liver histology (30) . Before pioglitazone initiation, plasma ALT reductions were already observed but were similar for all groups, as plotted in Fig. 1(a) . Mean plasma aminotransferase levels did not significantly increase during the 3-year follow-up, either in patients who were started on or were already receiving a statin at study enrollment.
In patients randomly assigned to placebo [ Fig. 1(b) ], mean plasma ALT levels remained abnormally elevated (.40 IU/L) throughout the first 18 months. Of note, patients not receiving a statin showed persistently higher levels of plasma ALT compared with patients taking a statin. The difference in plasma ALT levels between patients not receiving statins and those who started statin treatment occurred early (it reached statistical significance by the end of the run-in phase; P = 0.002) and persisted for the first 18 months of follow-up. This reduction in plasma ALT during the run-in in patients starting statins was associated with weight loss as mentioned above [ Fig. 1(b) ]. All groups normalized their mean plasma ALT levels after pioglitazone initiation in the open-label phase. Those patients who had started a statin during the study showed a nonsignificant increase in plasma ALT at month 24 that decreased spontaneously at months 32 and 34. An overall similar pattern was observed when plasma AST levels were plotted over time (Fig. 2) .
For further analyses, we took into account patients who showed at least a doubling of ALT/AST levels during follow-up. Overall, five patients showed at least a twofold increase in liver enzymes levels after the run-in phase (including the above-mentioned patient who was discontinued for this reason). Two of these five patients were not receiving a statin when their plasma aminotransferase levels increased. Of the other three, two were already taking a statin at enrollment, and only one was newly started on the medication. In all cases, liver aminotransferases returned to normal without a change in the statin dosing. Regarding muscular adverse events, 11 patients reported muscle cramps or muscle aches. None of these patients had an elevation in plasma creatine phosphokinase, and symptoms spontaneously resolved without any treatment.
Long-term efficacy
To assess possible long-term beneficial effects of statins in patients with NASH, we compared clinical and laboratory measures of patients who started a statin during the study and had not been randomly assigned to active medication (pioglitazone) during the trial ( Table 2) .
As expected, after 18 months of statin use, all lipid measures improved. Both plasma ALT (66 6 8 IU/L vs 38 6 5 IU/L; P , 0.001) and AST (48 6 6 IU/L vs 31 6 3 IU/L; P = 0.006) levels improved significantly after 18 months of statin therapy. This remained true when we analyzed the proportion of patients with abnormal plasma ALT concentration (ALT . 40 IU/L) before and after 18 months of follow-up. In agreement with this biochemical improvement, liver fat by 1 H-MRS also decreased after 18 months (13% 6 2% vs 8% 6 2%; P , 0.001). These improvements were strongly associated with changes in BMI [35.1 6 0.9 kg/m 2 vs 34.6 6 0.9 kg/m 2 (P = 0.06), corresponding to a reduction of 1.5 kg] and a small but significant improvement in the suppression of free fatty acids by low-dose insulin during the euglycemic insulin clamp (41% 6 5% vs 49% 6 4%; P = 0.02). Liver and skeletal muscle insulin resistance did not change after 18 months of statin therapy. None of the above changes in plasma ALT or liver fat by 1 H-MRS translated into any histologic improvement in the NAFLD activity score (3.9 6 0.3 vs 3.7 6 0.5; P = 0.40) or any of the individual components of the score: steatosis (1.7 6 0.2 vs 1.4 6 0.2; P = 0.10), inflammation (1.5 6 0.1 vs 1.6 6 0.2; P = 0.50), and ballooning (0.8 6 0.1 vs 0.7 6 0.1; P = 0.43). There were also no differences in fibrosis stage (0.6 6 0.2 vs 0.5 6 0.2; P = 0.50). Of note, we observed no significant metabolic or histologic changes among patients already receiving a statin at enrollment who continued statin therapy for 18 months (Table 3) .
Discussion
Health care providers commonly face the clinical dilemma of elevated plasma aminotransferases in an obese patient with the MetS and/or T2DM. Moreover, this situation is likely to increase in parallel with the worsening of the epidemics of obesity and T2DM. Clinicians are confronted with prescribing a statin to a patient with high cardiovascular risk vs withholding such treatment in the face of a perceived risk for harm in the setting of NASH. Few studies have served as guidance, and most of these suffered from many limitations: retrospective nature, small sample size (5 to 43 patients), short follow-up (mostly 6 to 12 months), and/or use of surrogate markers of liver disease (AST/ALT or liver imaging) rather than the gold standard, liver biopsy (12, 15-22, 24-28).
The current report is the largest prospective study assessing the safety of statins in patients with biopsy-proven NASH, with a cohort of 101 patients closely followed for a total follow-up of 194 patient-years. Our results offer compelling evidence that statins can be safely used in patients with NASH and should not be denied to these patients, who already have a very high risk for cardiovascular disease.
At enrollment, we found that only 37% of patients were receiving a statin, with an additional 12% receiving other lipid-lowering therapies. This very low use of statins among patients with NASH is in accordance with prior studies (12) . Of note, this low statin use occurred despite a high prevalence of obesity (81%), T2DM (51%), and MetS (89%). For instance, most patients had dyslipidemia; 55% had a plasma LDL-C level . 100 mg/dL, 59% had a plasma triglyceride level . 150 mg/dL, and 74% had an HDL-C level ,40 mg/dL (men) or ,50 mg/dL (women). There are several potential explanations for this. On the one hand, patient adherence to lipid-lowering therapy remains a challenge (38) . It is also well established that primary care providers may not be aggressive enough in starting or upwardly titrating statin therapy to meet established treatment goals (39) . Female patients appear to be at particular risk for statin therapy undertreatment, despite compelling evidence suggesting a similar benefit with statin therapy in both sexes (40, 41) .
However, the most likely cause (expressed by many referring primary care physicians) was the concern over safety of prescribing lipid-lowering agents in the face of elevated liver enzymes or knowledge that the patient had NASH. Supporting this view, there was an inverse correlation between the magnitude of the liver aminotransferase elevation in patients with NASH and the use of statins: Whereas 36% of patients were receiving statins at enrollment, this percentage declined to 33% and 21% when patients with plasma ALT . 40 U/L or . 80 U/L were respectively considered. Despite higher plasma aminotransferases and liver fat content by 1 H-MRS in statin nonusers, both statin users and nonusers had similar severity of liver disease at baseline based on histology. This indicates that elevated plasma aminotransferases and imaging (even 1 H-MRS) poorly reflect liver disease in NASH and offer inadequate information with which to make clinical decisions. This discordance between aminotransferases and histology has been reported before in clinical trials (42) (43) (44) . The National Lipid Association Statin Safety Assessment Task Force clearly stated that patients with NAFLD or NASH may safely receive statin therapy, recommending their use, but there is still strong resistance to do so in clinical practice (45) . In the current study, 75% of patients not taking a statin at enrollment were safely prescribed one. Because of this, our results are important in creating a paradigm shift for the use of statins in patients with NASH.
Most patients receiving a statin at study entry were not at goal (Table 1) . About a third had a plasma LDL-C level .100 mg/dL, .50% had an elevated plasma triglyceride concentration, and as many as two thirds a low HDL-C level. Indeed, in 75% the plasma non-HDL-C level was .100 mg/dl. Again, lack of upward statin titration was related to the fear of liver toxicity in patients with elevated plasma aminotransferases. However, after a 3-year follow-up period, statin therapy proved to be safe. The fact that more patients were able to reach plasma LDL-C rather than the non-HDL-C target highlights the difficulties of improving plasma triglyceride and HDL-C concentration in such patients and the potential for combination therapy with fibrates in this population. Fibrates, with or without statins, have been tested for the treatment of NAFLD, with rather neutral effects on liver fat content on imaging or histology; however, in some reports plasma aminotransferases were reported to decrease (46) . In this regard, no patient receiving combination therapy experienced a significant increase in creatine phosphokinase or liver enzymes. Taken together, fibrates also appear to be safe when added to statins in this population.
Finally, there has been some interest in the potential role of statins to improve liver histology in NASH and biochemical measures. In cell culture and animal models, statins may improve NASH by several potential mechanisms (10). For instance, in macrophages and monocytes, statins activate the peroxisome proliferator-activated receptor g (47) . They also activate peroxisome proliferatoractivated receptor a and promote fatty acid oxidation in vivo (48) . Other possible mechanisms include improvement of plasma levels of tumor necrosis factor-a, interleukin-6, and C-reactive protein, markers frequently associated with advanced histology in NASH (49) . However, it is unlikely that statins have a major effect on liver histology in humans with NASH. Although several uncontrolled studies have reported reductions in plasma aminotransferases and steatosis on imaging, these reports were characterized by their small numbers of patients, concomitant use of lifestyle intervention, lack of appropriate controls, and short follow-up (8, 29) . Confirming that statins do not improve liver histology in NASH, patients in the placebo group receiving statins had no significant change in hepatic steatosis, necroinflammation, or fibrosis after 18 months of follow-up.
The modest reduction in plasma aminotransferases and hepatic triglyceride content by 1 H-MRS that we observed in these patients ( Table 2 ) was likely related to weight reduction in this subset of patients [BMI, 35.1 6 0.9 kg/m 2 vs 34.6 6 0.9 kg/m 2 (P = 0.06), corresponding to a reduction of 1.5 kg in body weight]. Moreover, the ALT/AST changes we report are similar to those in the placebo groups of other RCTs in patients with NASH. For instance, in our prior RCT of pioglitazone vs placebo in patients with NASH (43), plasma ALT and AST also improved in the placebo group from 61 to 40 IU/L (P = 0.03) and AST from 42 to 33 IU/L (P = 0.08). Reductions of plasma ALT/AST of similar magnitude have been reported for the placebo groups of the PIVENS (42) and FLINT (50) trials in patients with NASH. These findings suggest that a small decrease in plasma aminotransferases is to be expected in placebo-treated patients and highlight the need for adequate controls in intervention studies in patients with NASH. Although we recognize that this study is a post hoc analysis of a randomized, single-center study with a relatively small sample size, the difficulty of performing paired percutaneous liver biopsies makes this current work the largest prospective study assessing the histologic safety of statins in patients with NASH. Statin adherence was not formally assessed during follow-up, but study drug adherence was overall good (95% by pill counting), suggesting a similarly high rate of adherence for statin use.
In summary, in the largest prospective study to date in patients with biopsy-proven NASH, we report that statins can be safely prescribed in this population. These are timely findings that call for a change in current practice as patients with NASH have the highest cardiovascular risk but dyslipidemia remains often undertreated. We hope that this work will increase awareness about the need for and safety of statin use in patients with NASH and that in the future they will not be deprived from this much-needed therapy. However, more work is needed to fully understand the role of statins in this setting.
